During this segment, Peter Salgo, MD; John L. Fox, MD, MHA; Ira M. Klein, MD, MBA, FACP; Michael Kolodziej, MD; Bryan Loy, MD; and Irwin W. Tischler, DO, note that the Centers for Medicare & Medicaid Services (CMS) is prohibited from considering the costs of therapy when evaluating whether to cover a new treatment option. The panelists also consider how the use of comparative effectiveness research (CER) may help address the financial challenges in medical oncology.
Drs Fox and Tischler explain that legislation currently prohibits CMS from considering cost when deciding whether to cover a treatment option. Dr Fox adds that this poses a problem, as new options can be expensive, yet lawmakers do not want to raise taxes. However, he says, taxpayers are still affected because private payers are forced to increase premiums to cover expensive drugs.
Higher patient costs (eg, co-pays) are associated with higher rates of nonadherence to therapy, notes Dr Klein. Thus, the cost of treatment creates an informal form of rationing. CER could be used to help address these challenges, comment Drs Fox, Klein, and Tischler, by identifying the most cost-effective therapies.
However, Dr Loy explains that because research is ongoing and additional drugs are in the pipeline, CER may not always be relevant or up-to-date. In the absence of CER data, the main drivers that affect treatment decisions include costs and side-effect profiles.
In terms of end-of-life and palliative care discussions, Drs Fox, Kolodziej, and Loy agree that the cancer care team can help reduce the financial burden of oncology treatments on patients and their families by discussing priorities and care preferences earlier in the patient’s course of care, and routinely delivering additional information over time.
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More